EHR

New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows

BOTHELL, Wash., June 20, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.’s (Nasdaq: COCP) novel, broad-spectrum antiviral CC-42344 inhibits activity in…

6 months ago

AUROBAC THERAPEUTICS APPOINTS SCIENTIFIC ADVISORY BOARD

The newly formed Scientific Advisory Board chaired by Dr. Marco Taglietti will provide technical and strategic guidance to support AUROBAC’s…

6 months ago

LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

UTRECHT, The Netherlands and PHILADELPHIA, June 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on…

6 months ago

BIOLASE Announces Delisting from Nasdaq

LAKE FOREST, CA / ACCESSWIRE / June 18, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a global leader in dental lasers, today…

6 months ago

Healthcare BPO Market Anticipates USD 626.6 Billion by 2029 with 9.7% CAGR | MarketsandMarkets™

CHICAGO, June 18, 2024 /PRNewswire/ -- The Healthcare BPO market is projected to grow from USD 395.3 billion in 2024 to USD…

6 months ago

Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) today announced that interim data from the open-label real-world LOTUS™ study will be…

6 months ago

EHEALTH TECHNOLOGIES PARTNERS WITH CANCERX AND WHITE HOUSE CANCER MOONSHOT

PITTSBURGH, June 17, 2024 /PRNewswire/ -- eHealth Technologies -- a leading healthcare technology company that provides a patented cutting-edge technology…

6 months ago

Parachute Health Launches Integrated Solution of DME Ordering with Prior Authorization

Newly Embedded Prior Authorizations in the Parachute Platform Reduce Costs and Streamlines Administration for Health Plans, DME/HME Providers, and Clinicians NEW…

6 months ago

Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress

– ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia – – Additional…

6 months ago